Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring.
about
Effectiveness of influenza vaccination for preventing influenza-related complications in people with asthma: a systematic review protocolThe Saudi Thoracic Society guidelines for influenza vaccinationsFrequently asked questions on seven rare adverse events following immunization."Prepandemic" immunization for novel influenza viruses, "swine flu" vaccine, Guillain-Barré syndrome, and the detection of rare severe adverse eventsA review of the changes to the licensing of influenza vaccines in Europe.Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project.The 2009 pandemic H1N1 influenza vaccination in France: who accepted to receive the vaccine and why?Self-reported adverse reactions in 4337 healthcare workers immunizations against novel H1N1 influenza.No evidence of a link between influenza vaccines and Guillain-Barre syndrome-associated antiganglioside antibodiesThe importance of influenza prevention for public health.[Guillain-Barré syndrome after exposure to influenza].First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.The PREGVAXGRIP study: a cohort study to assess foetal and neonatal consequences of in utero exposure to vaccination against A(H1N1)v2009 influenza.Safety of pandemic (H1N1) 2009 monovalent vaccines in taiwan: a self-controlled case series study.Deaths following vaccination: What does the evidence show?Analysis of Individual Differences in Vaccine Pharmacovigilance Using VAERS Data and MedDRA System Organ Classes: A Use Case Study With Trivalent Influenza Vaccine.Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16.Clinical Features of Post-Vaccination Guillain-Barré Syndrome (GBS) in Korea.Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines.From the patient perspective: the economic value of seasonal and H1N1 influenza vaccination.Introducing seasonal influenza vaccine in low-income countries: an adverse events following immunization survey in the Lao People's Democratic Republic.Influence of Granulocyte-Macrophage Colony-Stimulating Factor or Influenza Vaccination on HLA-DR, Infection and Delirium Days in Immunosuppressed Surgical Patients: Double Blind, Randomised Controlled Trial.Technical guidelines for the application of seasonal influenza vaccine in China (2014-2015).Risk of anaphylaxis after vaccination in children and adultsPost-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015Influenza vaccination: key facts for general practitioners in Europe-a synthesis by European experts based on national guidelines and best practices in the United Kingdom and the Netherlands.Evaluating the effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination: protocol for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study.Administering influenza vaccine to egg-allergic persons.Viral RNA in the influenza vaccine may have contributed to the development of ANCA-associated vasculitis in a patient following immunisation.A case of myositis of the deltoid muscle of the upper arm developing 1 week after influenza vaccination: case report.The "urban myth" of the association between neurological disorders and vaccinations.Health-care worker vaccination for influenza: strategies and controversies.Trivalent influenza vaccine adverse symptoms analysis based on MedDRA terminology using VAERS data in 2011.Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 μg) in two European countries during influenza season 2016/17 and comparison with 2015/16 season.Mandatory influenza vaccination for health care workers as the new standard of care: a matter of patient safety and nonmaleficent practice.A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries.Comparison of response rates on invitation mode of a web-based survey on influenza vaccine adverse events among healthcare workers: a pilot study.Neurologic adverse events following influenza A (H1N1) vaccinations in children
P2860
Q28077038-B08D9E22-D449-4142-A8D1-33025C6F3A14Q28394218-BDE9AE31-831E-497F-A05E-AB9EEF320A9EQ30234430-2D9E9BEE-F725-4E04-82AB-DCBCDDF346F0Q30378494-4CFB1C1C-B8D5-48B5-BEE5-95EAEAC5E287Q30379967-E02A59DC-E5FC-4345-B649-4EFB1CA1128EQ30383245-8F01EAA6-5BDD-4AE7-BFA5-4127F14E0DB0Q30395206-8F79C8E0-47F6-4E76-AE5B-A51BCB1AB55CQ30406071-AADCA514-7966-4A03-83A9-DB87182D2AB1Q30407561-F5490276-87C6-430E-966F-93F24935A3F0Q30411857-EA6FFA0E-688F-465A-A694-61B9E8C5A522Q30415924-54A13F2F-0C3B-403D-B408-7949985E7E9EQ30421150-15BF58C7-F6E8-4740-8DC7-64916D209356Q30428542-A9280CC1-150F-44C2-BCD4-2AC4B6E0B229Q30428839-9F79376F-3788-4DC7-8CDF-DABB3989D031Q33165769-0F20E62E-9CE1-49B1-A20A-BD30306CF37CQ33563415-B5EE939B-4565-46C0-BC7F-D9D135BAD458Q33698062-22793A4E-A226-4C21-8244-80DFDC148A4AQ33770375-D54B2933-279A-42F1-A4E6-B3A2130D8D3BQ34499848-BD004194-3F94-43D3-9906-7FA96D9BA73AQ34613417-A34D31DF-38E6-4AD7-ADB9-C666159FF277Q35158308-F3C542C1-D5E5-4C47-88E8-233840DE4283Q35862144-3974710D-4C2F-460F-A706-9EF04A90ADA8Q36256314-58B41F1E-3082-4E2C-9E30-1F894F41D571Q36665226-818D13A8-DD69-4D6D-9413-E21F34DE7544Q37027049-49040BE6-6BAD-4C0F-9EF2-760B34C40D89Q37152931-FB9542A9-2F99-4004-A466-8B56659C3844Q37681302-762AD07D-AE9C-417B-AE17-196625644F20Q38222967-BAFB8E6D-CBD7-4E7A-BCB2-66B423A63FC2Q41371533-FEC28398-8071-4A24-9304-B13AA0EFE94FQ41844412-94B599BA-813A-44D1-98EB-814035C60DF7Q43080823-A7282B2E-E0DB-4B4A-BA20-B05A1635FF1DQ44978409-6366EC60-1015-4659-8A11-36BDE9F8051CQ45866785-DE24C35D-F9B5-4536-8806-E1092A9F6D7CQ47579328-8427E33A-7E1C-4B00-ACCA-D872E2ED0E7CQ54455606-3F5DDC54-7AFF-47CD-966D-75216BC4A887Q54626497-21CC57BC-2CFE-4FCB-BA91-FAEDA94AE7BBQ55317554-45047D16-6860-4D17-9670-91E53246CFACQ57101873-91D9E93E-5B59-45B8-AD4C-1C62CF2157D9
P2860
Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Safety of trivalent inactivate ...... nza vaccine safety monitoring.
@ast
Safety of trivalent inactivate ...... nza vaccine safety monitoring.
@en
type
label
Safety of trivalent inactivate ...... nza vaccine safety monitoring.
@ast
Safety of trivalent inactivate ...... nza vaccine safety monitoring.
@en
prefLabel
Safety of trivalent inactivate ...... nza vaccine safety monitoring.
@ast
Safety of trivalent inactivate ...... nza vaccine safety monitoring.
@en
P2093
P1433
P1476
Safety of trivalent inactivate ...... nza vaccine safety monitoring.
@en
P2093
Azra Dobardzic
Claudia Vellozzi
Dale R Burwen
Kimp Walton
Penina Haber
Robert Ball
P304
P356
10.1016/J.VACCINE.2009.01.125
P407
P577
2009-02-06T00:00:00Z